openPR Logo
Press release

Sarcopenia Treatment Market Expansion to be Persistent During 2026 With Top Players GlaxoSmithKline, Radius Health, Five Prime Therapeutics, Abbott Laboratories, Pfizer, Nestle S.A., Sanofi S.A., Bayer AG, and Novartis AG, Cadila Healthcare

07-05-2019 04:31 PM CET | Health & Medicine

Press release from: Coherent Market Insights - Pharmaceutical Industry

Sarcopenia Treatment

Sarcopenia Treatment

Sarcopenia means loss of skeletal muscle mass or loss of flesh by aging. Sarcopenia is associated with functional impairments in tasks such as standing up from a chair or lifting 10 pounds and physical disabilities such as not able to perform home chores and personal care. The loss of muscle tissue may progress more rapidly after the age of 60 or 70, however the exact rate of decline may vary, and a person may lose 3-8% of muscle mass per decade.

Ask For Sample Copy of This Business Report : https://www.coherentmarketinsights.com/insight/request-sample/2770

Symptoms of Sarcopenia include decrease in muscle size, weakness, loss of endurance, trouble in climbing stairs and poor balance. As such there is no approved treatment available for sarcopenia, however nutrition and dietary supplements can play an important role in its treatment. Nutrition prevents accelerated muscle loss during the period of muscle disuse and maintains energy levels. Some of the important supplements for treating sarcopenia include proteins, amino acids, creatine, omega 3 acid, vitamin D and B12, and calcium carbonate.

Sarcopenia Treatment Market Drivers

Increasing geriatric population is expected to boost growth of the sarcopenia treatment market growth. According to the World Health Organization, by 2050, the world’s population aged 60 years and above is expected reach 2 billion from 900 million in 2015. The conferences, meetings held by the foundations help to expand and share the knowledge and information about the sarcopenia treatment which will in turn drives the growth of sarcopenia treatment market. For instance, in April 2017, the U.S. Food and Drug Administration (FDA) held its public meeting on Patient Focused Drug Development (PFDD) for sarcopenia. The focus of the meeting was to obtain patient perspectives on symptoms and daily impacts of their condition.

Increasing investments in production of drugs and supplements are expected to boost growth of the sarcopenia treatment market. Furthermore, a growing number of pharmaceutical and food processing companies are focused on developing nutrition supplements for treatment of sarcopenia.

Malnutrition and vitamin deficiency in developing countries is expected to boost growth of the sarcopenia treatment market. Reduction of hormone secretion rate and increasing vitamin deficiency as a result of aging are expected to create high demand for sarcopenia treatment supplements. Economic factors such as rise in consumer spending by the geriatric population, and increasing per capita healthcare expenditure are expected to drive demand for sarcopenia treatment supplements.

Sarcopenia Treatment Market Key Players

Some of the major players operating in the sarcopenia treatment market include GlaxoSmithKline, Radius Health Inc., Five Prime Therapeutics, Inc., Abbott Laboratories, Pfizer Inc., Nestle S.A., Sanofi S.A., Bayer AG, and Novartis AG, Cadila Healthcare Ltd.

Sarcopenia Treatment Market Regional Analysis

North America is expected to hold a dominant position in the sarcopenia treatment market, owing to presence of developed healthcare facilities and infrastructure in countries such as the U.S, and Canada. Moreover, the demand for sarcopenia treatment has increased in the region due to high focus on healthcare by the government, technological advancements are likely to fuel growth of the sarcopenia treatment market during the forecast period.

Request Customization : https://www.coherentmarketinsights.com/insight/request-customization/2770

Europe is expected to be the second largest sarcopenia treatment market over the forecast period. For instance, in February 2019, Biophytis SA, a Paris (France) based company focused on development of novel therapeutics for age-related diseases, announced three oral and poster presentations at the 2019 International Conference on Frailty and Sarcopenia Research (ICFSR). In this conference, the company presented the details of its lead clinical drug candidate, Sarconeos (BIO 101), that included its history and unique mechanism that targets the MAS receptor for preservation of muscle function in muscle wasting disorder. In addition, the company also presented the clinical trial design of its ongoing SARA Phase 2 study of Sarconeos to treat sarcopenia.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Sarcopenia Treatment Market Expansion to be Persistent During 2026 With Top Players GlaxoSmithKline, Radius Health, Five Prime Therapeutics, Abbott Laboratories, Pfizer, Nestle S.A., Sanofi S.A., Bayer AG, and Novartis AG, Cadila Healthcare here

News-ID: 1798009 • Views: 868

More Releases from Coherent Market Insights - Pharmaceutical Industry

Radiopharmaceuticals in Nuclear Medicine Market Advancements to Watch Out For 20 …
Coherent Market Insights released a new market study on 2018-2026 Radiopharmaceuticals Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Ask For Sample Copy of Research
Outsourced Drug Discovery Market: Latest Advancements & Market Outlook 2019 to 2 …
Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development. Ask For a Sample Copy of This Business Report @
Cannabis Testing Services Market: New Business Opportunities and Investment Rese …
Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players. Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2976 Market
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around

All 5 Releases


More Releases for Sarcopenia

The Sarcopenia Treatment Market to be digitally servile
The Sarcopenia Treatment Market is bound to grow at a remarkable rate in the forecast period. Vital Sign monitoring, in combination with wearables, does aid in symptoms check-in as well as education 24/7. There are also hand-held dongles being made available for attaching to smartphones to measure biomarkers for chronic ailments. This monitoring proves to be more cost-effective and convenient in comparison with in-person care. This trend would be prevalent
Sarcopenia Market Scope Emerging Trends, Analysis and Forecast 2026
The report published on the “Sarcopenia Market Scope Emerging Trends, Analysis and Forecast 2026” by Zion Market Research facilitates a closer outlook on opportunities, revenue growth, and current market trends. The report is focused to offer qualitative and quantitative analysis of dynamics and market opportunities prevailing during the forecast period. Also, the report encompasses an in-depth study on the prominent leaders in the Sarcopenia Market. The Leading Market Players Covered
Sarcopenia Treatment Market to Witness Significant Incremental Opportunity
According to a recent report published by Research Dive, titled, "Sarcopenia Treatment Market by Type, and Application: Global Opportunity Analysis and Industry Forecast, 2018-2025," the global Sarcopenia Treatment market size was valued at $ 2742.4 million in 2018, and is projected to reach $ 3975.0 million by 2026, registering a CAGR of 4.7% from 2018 to 2026. North America dominates the market, followed by Europe, Asia-Pacific, Latin America, Middle East and
Sarcopenia Treatment Market Analysis & Key Trends 2025
Sarcopenia which results in the decrease of lean muscle mass when the person reaches age thirty or above, she or he could expect the gradual loss of muscle tissues due to increasing aging altering the level of activity and also affecting the quality of life. Aging leads to change in metabolic activity which includes the decrease in synthesis of muscle protein and little change in the degradation. Sarcopenia affects
Sarcopenia Pipeline Review H2 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia - Pipeline Review, H2 2017, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape. Sarcopenia is defined as the loss of mass and muscular function with age. Symptoms include obesity, difficulty walking or moving about, lack of strength and respiratory problems. Treatment includes medications and hormone replacement therapy. Publisher's Pharmaceutical and Healthcare latest pipeline guide Sarcopenia - Pipeline Review, H2 2017,
Sarcopenia Treatment Market: Upcoming Demands and Growth Analysis 2025
Sarcopenia is the loss of muscle mass and muscle strength as a person reaches age thirty or more, in response to aging, affecting the level of activity and quality of life. It has been identified in three stages in older people: presarcopenia-loss of muscle mass, sarcopenia-loss of muscle which can affect either physical performance or physical strength, and severe sarcopenia-loss of muscle mass that affects both physical performance and strength.